Status:
ACTIVE_NOT_RECRUITING
Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Metabolism Disorder
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Recent EMA and FDA approvals have made immune checkpoint inhibitors (ICI) a standard of care in cancer treatment. ICI, used alone or as a combination are now the backbone of renal cell and lung carcin...
Eligibility Criteria
Inclusion
- patients ≥18 years
- patients receiving immune checkpoint inhibitors, used alone or as a combination with chemotherapy or tyrosine kinase inhibitor or other immune checkpoint inhibitor, for advanced renal cell or lung carcinoma.
- Patient Informed and signed the consent to participate in the research
Exclusion
- patients with history of auto immune disease
- patients enrolled in an interventional study or be in the exclusion period following a previous research, if applicable
- Patient not affiliated to the social security scheme or under AME
- Patient under guardianship or curatorship or under legal protection
- Patient unable or unwilling to give written consent
- Pregnant patient
- be in the exclusion period following a previous research, if applicable
Key Trial Info
Start Date :
May 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 9 2024
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04808817
Start Date
May 10 2021
End Date
October 9 2024
Last Update
July 11 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Cochin
Paris, Île-de-France Region, France, 75014
2
AP-HP - Hôpital Européen Georges-Pompidou Paris
Paris, Île-de-France Region, France, 75015